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Editorial
Adiposity and Cardiometabolic Outcomes
What CanMeta-analyses of Mendelian Randomization
Studies Contribute?
Kaitlin H. Wade, BSc, PhD; George Davey Smith, MD, DSc, FFPH
In the study by Riaz et al,1 evidence was presented for a potential causal role of obesity (determined
by bodymass index [BMI]) on increasing the risk of type 2 diabetes (T2D) and coronary artery disease
(CAD) in over 800000 individuals in ameta-analysis of 5 studies. Specifically, authors screened over
2500 articles and conducted a systematic review of 7 studies andmeta-analysis of 5 studies
(including a total of 881 269 individuals) that usedMendelian randomization (MR) methodology to
assess the potential causal role of anymeasure of adiposity in the incidence of cardiovascular events,
including T2D, CAD, and stroke.
The association between obesity (or, indeed, anymeasure of adiposity) and cardiovascular
outcomes has been assessed primarily with large-scale observational studies, which have limitations
such as confounding (external factors that associate with both obesity and cardiovascular
outcomes), reverse causation (where disease leads to increased adiposity), andmany forms of bias
(especially, in this context, selection bias). Furthermore, interventions and trials that aim to lower
BMI are inherently difficult andmany have proven unsuccessful in achieving sustained weight loss of
a magnitude and duration that could be expected to reduce cardiovascular events or mortality.
Increasingly, studies have used an alternative approach—MR—to overcome these limitations and help
strengthen causal inference (Figure),2,3 particularly within the field of cardiometabolic health. The
MRmethodology exploits the properties of genetic inheritance tomimic a randomized clinical trial to
improve causal inference (see the 2-minute primer onMRmethodology for a basic description and
for further details3,4). ManyMR studies have provided evidence of higher adiposity increasing the risk
of adverse cardiovascular outcomes, with some inconsistencies, possibly owing to low
statistical power.





Genetic variants (Z) is used as an instrumental variable for an exposure (X) to assess its causal role on an outcome of
interest (Y). Mendelian randomizationmethodology relies on the following 3 key assumptions: (1) Z is associatedwith X, (2)
Z is independent of measured or unmeasured confounders—U, and (3) Z only influences Y through its effect on X. In a
1-sample setting, individual-level data on genetic variation, exposure, and outcome are present in 1 sample of individuals.
In a 2-sample setting, summary-level estimates of the genotype-exposure association and the genotype-outcome
association are obtained from 2 independent samples usually from genome-wide association studies, and individual-level
data are not needed.
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Riaz et al1 searched bothMEDLINE and Scopus for studies (up to January 2018), retrieving
articles that performedMR analyses to assess the association between anymeasure of obesity (BMI
or waist to hip ratio) and cardiometabolic outcomes (CAD, stroke, and T2D), and provided
appropriate summary statistics for performance of systematic review andmeta-analysis.
Of the 2511 studies that remained after initial screening, 7 studies met a priori criteria for
inclusion in their systematic review and 5 studies met inclusion criteria in the meta-analysis for the
association of obesity with T2D, CAD, and stroke. Results provided evidence for an effect of obesity
(specifically, each 1-SD-higher BMI) on T2D (odds ratio, 1.67; 95% CI, 1.30-2.14; P < .001; I2 = 93%;
n = 461 871) and CAD (odds ratio, 1.20; 95% CI, 1.02-1.41; P = .03; I2 = 87%; n = 570 261), but no
evidence for an effect on stroke (odds ratio, 1.02; 95% CI, 0.95-1.09; P = .65; I2 = 0%; n = 228816).
The authors defined severe heterogeneity as an I2 statistic of greater than 75%. While there was
consistent and nonheterogeneous evidence regarding the lack of a clear effect of obesity on stroke,
the evidence for the effect of obesity on T2D and CAD were considered severely heterogeneous by
this definition. The authors state that this heterogeneity was anticipated given the variation in study
methodologies, participants, localities, and selection of genetic variants. Additionally, while the
authors initially searched for studies that assessed the impact of multiple measures of adiposity, only
those that focused on BMI passed inclusion criteria. Future work focusing on multiple measures of
adiposity (such as waist to hip ratio, fat mass, and lean mass indices) and methods such as
multivariable MRmay help decipher the effect of differential body composition on cardiometabolic
outcomes.5
As the authors state, there are no standardized tools to ascertain the risk of bias of MR studies
included in meta-analyses; thus, to assess the quality of studies included, Riaz et al1 evaluated the
heterogeneity between studies for each outcome and whether the 3 keyMR assumptions had been
met (Figure). However, 2 of these assumptions were grouped together but are different concepts
and should be treated as such. Assumption 2 (as defined by the authors) says that the genetic
instrument should be independent of confounders, while assumption 3 says that the genetic
instrument should affect the outcome only through the exposure (otherwise known as horizontal
pleiotropy). In a 1-sample setting with rich individual-level data, it is possible to test the presence or
absence of an association with measured confounding factors, which provides some evidence
regarding assumption 2 (although, of course, unmeasured confounders could be associated with the
genetic variants even if the measured confounders are not). With the drive toward using 2-sample
MRmethods, it is increasingly difficult to examine this important assumption, even in the incomplete
way it can be interrogated in 1-sample settings. However, with this samemove toward 2-sample MR
analyses, there are increasing methods of subjecting the third assumption—absence of horizontal
pleiotropy—to sensitivity analyses, whichmay require less stringent assumptions to hold. In addition
to the referenced weightedmedianmethod they discuss, there are other approaches that aim to
assess and/or account for horizontal pleiotropy, including the weightedmode6 andMR-Egger7
analyses.
As part of their criteria to be included within their qualitative systematic review, the authors
required that a minimum of 2 studies reported an association between a measure of adiposity and
cardiovascular events in nonoverlapping data. In the casewhere 2 ormore studies used data from the
same source or biobank, only the larger onewas included in the quantitativemeta-analysis. However,
it is worth noting that, by the definition of these criteria, therewas some study overlap in the articles
contributing to the qualitative systematic review. Specifically, 2 articles used over 110000
participants fromUK Biobank and 2 articles used studies from the European Network for Genetic and
Genomic Epidemiology Consortium.While there was no explicit overlap in the studies that
contributed to the current meta-analysis, it is worth noting that as MR studies become larger, the
likelihood of contributory articles including overlapping individuals becomes greater and will lead to
overprecise estimates. The UK Biobank, for example, will contain individuals in some of the other
UK cohorts that are included in themeta-analysis, illustrating that double counting of some
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participants will already be occurring. Methods such as linkage disequilibrium score regression8 will
be important in estimating the extent of bias that such overlap could induce.
Future considerations of studies using MRmethodology include the involvement of low- to
middle-income countries, testing linearity of associations and identifying risk factors for disease
progression (other than solely disease onset). First, a majority of MR studies include solely or largely
individuals of European ancestry but, as the authors wrote, cardiovascular diseases are increasingly
the leading cause of morbidity and mortality in the developing world. Therefore, future research
should consider including data from low- to middle-income countries to ensure relevance to those
settings.9
Second, MR studies typically assume linearity in all associations (ie, the genotype-exposure and
exposure-outcome relationships), whichmay be inappropriate in some cases. With recent
methodological developments, linearity can be assessed in anMR context10 as in a recent study
estimating the possible effect of BMI on all-cause and cause-specific mortality (including
cardiovascular diseases) in the UK Biobank.11 Suchmethods can also challenge the so-called “obesity
paradox”, whereby overweight individuals have the lowest mortality, risk of certain diseases, or
adverse outcomes of disease comparedwith thosewho are within the normal weight range or obese,
which the authors mention but cannot investigate directly.
Third, the authors state the importance of identifying novel risk factors for primary and
secondary prevention of cardiovascular diseases. Most MR studies have focused on understanding
primary risk factors for disease owing to the lack of availability of genome-wide association studies
that focus on phenotypes that are directly related to disease progression and the complexities of
using MRmethodology in case-only contexts.12
An additional consideration relates to the use of categorical and/or binary variables as the
exposure in MR studies. While in the current meta-analysis, the authors attempted to assess the
effect of obesity on cardiovascular outcomes, the results presented relate to studies that estimated
the continuous effects of BMI on cardiovascular outcomes. By dichotomizing BMI into obese and
nonobese, in this instance, it is difficult to directly infer whether obesity itself causes variation in the
risk of cardiovascular events or merely that the underlying liability to obesity influences this risk.
Although in this case it is highly plausible that obesity has the effects ascribed to it, in other cases
such as using MR to assess whether schizophrenia risk influences cannabis use,13 the interpretation
that this shows “a causal influence of schizophrenia” is not justified (and is highly unlikely given the
low prevalence of schizophrenia). In this situation, interpretation is limited to underlying liability to
schizophrenia, not to schizophrenia itself. TheMR sensitivity analysis approaches remain useful tools
for indicating whether this association reflects liability in general or relates to specific genetic
variants.
The study by Riaz et al1 presents the first meta-analysis, to our knowledge, of MR studies
assessing the association between obesity and cardiovascular outcomes, reporting compelling
evidence that each 1-SD-higher BMI increased the risk of T2D by 67% and CAD by 20% but no strong
evidence for an effect on stroke. These results support a global effort to lower the increasing
population trends for excess weight and suggest that in most cases, any reduction in BMI is likely
beneficial.
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